Iconovo’s partner Amneal has taken the next important step in the clinical development of ICOres budesonide/formoterol

Iconovo announces that the company’s development partner Amneal Pharmaceuticals has completed a clinical pharmacokinetic pilot study comparing ICOres budesonide/formoterol and Symbicort Turbuhaler. The results from the study indicate that ICOres budesonide/formoterol will meet the criteria for demonstrating bioequivalence in an appropriately designed and powered study. The study represents an important step ahead of the initiation of a registration study of the product and Iconovo will proceed according to plan.

“We are pleased that our partner, the publicly listed U.S. pharmaceutical company Amneal Pharmaceutials, has taken this important step forward in the clinical development of ICOres budesonide/formoterol. The results from this study have provided the final piece of the puzzle to move forward with a pivotal study according to plan,” says Iconovo’s CEO, Johan Wäborg.

To read the full press release, please click here.